Tyler Robertson, D.O. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 Fax: 435-688-6222 |
William Wesley Barney, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2900 Fax: 435-251-2901 |
Dr. Jason Lindsay Hansen, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 |
Matthew Stilson Williams, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1380 E Medical Center Dr, St George, UT 84790 Phone: 435-251-2992 |
Sarah Wei Wu, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 577 S River Rd, St George, UT 84790 Phone: 435-688-6200 |
Dr. Kerri N Smith, DO Hospitalist Medicare: Medicare Enrolled Practice Location: 1380 E Medical Center Dr, Suite 3100, St George, UT 84790 Phone: 435-251-2740 |
News Archive
People with autism spectrum conditions (ASC) often show a reduced sensitivity to contextual information in perceptual tasks, but new research suggests that this reduced sensitivity may actually lead to more consistent choices in high-level decision-making tasks.
A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria.
New research reveals a high-resolution view of the Zika viral life cycle within infected cells and shows dramatic changes in the cell's architecture throughout the infection process. This novel perspective may lead to the development of new vaccines and treatments.
Potentially harmful and undeclared pharmaceuticals were identified in more than 700 over-the-counter dietary supplements in an analysis of U.S. Food and Drug Administration warnings from 2007 through 2016.
Onconova Therapeutics, Inc., a development-stage pharmaceutical company focused on discovering and developing novel small molecule drug products to treat cancer, today announced that tolerability and favorable anti-tumor activity data from a Phase 1 trial evaluating oral rigosertib, a dual pathway inhibitor, in patients with advanced solid tumors including refractory metastatic head and neck cancer were presented today at the American Association for Cancer Research Annual Meeting.
› Verified 1 days ago